"CORolla® - a disruptive ""spring like"" metallic device for permanent treatment of diastolic heart failure."

Información del proyecto

CORolla

Identificador del acuerdo de subvención: 832168

DOI

10.3030/832168

Proyecto cerrado

Fecha de la firma de la CE 28 Noviembre 2018

Fecha de inicio 1 Noviembre 2018

Fecha de finalización 28 Febrero 2019

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

CORASSIST CARDIOVASCULAR LTD
Israel

Periodic Reporting for period 1 - CORolla (CORolla® - a disruptive "spring like" metallic device for permanent treatment of diastolic heart failure.)

Período documentado: 2018-11-01 hasta 2019-02-28

Resumen del contexto y de los objetivos generales del proyecto

If a patient has diastolic heart failure, his left ventricle becomes stiffer than normal. Because of that, his heart can't relax the way it should. When it pumps, it can't fill up with blood as it's supposed to. Because there's less blood in the ventricle, less blood is pumped out to the body. This disfunction has very negative influence on the quality of life. It causes shortness of breath, tiredness, weakness, swelling of feet, ankles, legs, or abdomen, lasting cough or wheezing, fast or irregular heartbeat, dizziness, confusion, nausea, lack of appetite. It may lead to many complications including anemia, impaired kidney function or stroke. With diastolic heart failure, currently, there is no available treatment for the condition. The current practice involves only identifying and treating comorbidities (i.e. conditions such as hypertension, diabetes, etc.) associated with heart failure and symptomatic relief medications like use of diuretics. CORolla® - an elastic "spring-like" metallic device (Figure 1) which is implanted inside the Left Ventricle (LV) of the heart in a minimally invasive procedure. It is innovative device-based treatment for HFpEF (Heart failure with preserved ejection fraction) aimed at providing diastolic heart failure treatment. The overall objective is to clinically validate the medical device and reach market readiness.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

During the feasibility assessment, CorAssist has completed a full analysis of the technical, clinical and business potential of their CORolla® medical implantable device. Throughout the project, CorAssist has greatly expanded their knowledge regarding the clinical validation and regulatory approval required for the European market launch. The key technical milestone achieved during the project was the approval of safety and feasibility clinical investigation which would be sufficient to apply for the CE Mark. CorAssist also received and disseminated the results from first patient implanted with CORolla®.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

CORolla® is the first device designed to improve the impaired diastolic function which affects more than 13 million people worldwide. It is implanted in a one-time procedure improving patient’s quality of life, reducing morbidity and the need for frequent hospitalizations.

CORolla device

CORolla spring to treat diastolic heart failure